Efferon® LPS

Third-Generation Extracorporeal Adsorber

Restore Balance. Improve Outcomes. Reduce Costs.

- **Innovative Design:** Surface-modified hypercrosslinked polystyrene beads
- **Dual Mechanism:** Simultaneously targets both endotoxins and cytokines
- **Proven Clinical and Economic Value:** Demonstrated improvements in patient outcomes and reductions in ICU resource utilisation
- **Ready-to-Use:** Sterile, pyrogen-free, and compatible with standard CRRT, dialysis and perfusion machines
- **Reliable:** Polycarbonate column with standard connectors for easy integration and minimal error risk

Indications (CE Mark under EU MDR Requirements)

- **Sepsis** of verified or suspected gram-negative origin, including **septic shock**
- **Critical endotoxemia:** Elevated levels of endotoxin in the blood
- **Cytokine storm syndrome:** Elevated cytokines causing systemic inflammation

MODE OF ACTION:

Multimodal adsorbent beads selectively bind two dissimilar therapeutic targets: endotoxins and excess of inflammatory mediators (such as cytokines).



Bacterial endotoxins

Endotoxins are adsorbed via interaction with surface-immobilised synthetic LPS-selective ligand.

Cytokines and inflammatory mediators

Cytokines and cell debris are adsorbed via intrinsic porosity of hypercrosslinked polystyrene matrix.

NORRDIA

Clinical Benefits: Proven in the LASSO Trial

The safety and efficacy of the Efferon® LPS was studied in the LASSO multi-center randomised controlled trial.[1] Patients with abdominal sepsis complicated with septic shock (n=58) were randomised in two groups. The control group received standard of care treatment, while the intervention group received two Efferon® LPS hemoperfusions.









*Denotes p < 0.05

Economic Impact: Potential savings in healthcare resources

If the differences in healthcare resource utilisation observed in the LASSO trial were translated into monetary terms, the Efferon® LPS device could lead to a reduction of almost 40% per patient.



Based on a decision-analytic model using LASSO trial data and 2025 ICU cost estimates.[2]

For more information, please contact your NorrDia representative or visit our website.

1. Rey et al. Hemoperfusion Using the LPS-Selective Mesoporous Polymeric Adsorbent in Septic Shock: A Multicenter Randomized Clinical Trial. Shock. 2023;59(6):846-854.
2. Ethgen et al. Potential savings associated with faster septic shock resolution in the ICU: An exploratory analysis of extracorporeal hemoperfusion using the Efferon LPS device. Critical Care. 2025; 29(S1):P220.

Distributed by:

Nikkiso Belgium BV
Industriepark 6
3300 Tienen
Belgium

PM-0248-06/2025-1

Efferon OÜ
Harju maakond, Tallinn,
Kristiine linnaosa,
Mooni tn 18, 10613, Estonia

CE 2265